News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,203 Results
Type
Article (10759)
Company Profile (21)
Press Release (81875)
Multimedia
Podcasts (85)
Webinars (11)
Section
Business (34790)
Career Advice (551)
Deals (5989)
Drug Delivery (97)
Drug Development (12828)
Employer Resources (44)
FDA (1996)
Job Trends (2158)
News (50681)
Policy (4910)
Tag
2027 BioCapital Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (171)
Accelerated approval (11)
ADA (13)
Adcomms (21)
Allergies (40)
Alliances (8251)
ALS (49)
Alzheimer's disease (338)
Antibody-drug conjugate (ADC) (130)
Approvals (1959)
Artificial intelligence (201)
ASCO (58)
Autoimmune disease (69)
Automation (9)
Bankruptcy (54)
Best Places to Work (1202)
BIO (21)
Biologics (1)
BIOSECURE Act (9)
Biosimilars (88)
BioSpace Insights (59)
Biotechnology (13)
Bladder cancer (40)
Brain cancer (11)
Breast cancer (75)
Cancer (999)
Cardiovascular disease (157)
Career advice (459)
Career pathing (27)
CAR-T (53)
CDC (13)
Cell therapy (142)
Cervical cancer (5)
Clinical research (11113)
Collaboration (542)
Commercialization (2)
Company closure (1)
Compensation (118)
Complete response letters (37)
COVID-19 (460)
CRISPR (8)
C-suite (321)
Cystic fibrosis (14)
Data (1027)
Decentralized trials (1)
Denatured (13)
Depression (41)
Dermatology (34)
Diabetes (123)
Diagnostics (553)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (11)
Drug discovery (124)
Drug pricing (165)
Drug shortages (25)
Duchenne muscular dystrophy (85)
Earnings (10146)
Editorial (47)
Employer branding (6)
Employer resources (50)
Events (12566)
Executive appointments (274)
FDA (2527)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (350)
Gene editing (29)
Generative AI (37)
Gene therapy (134)
GLP-1 (490)
Government (844)
Grass and pollen (1)
Guidances (47)
Healthcare (1538)
Hematology (24)
HIV (18)
Huntington's disease (20)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (21)
Immunology and inflammation (154)
Immuno-oncology (37)
Indications (20)
Infectious disease (552)
Inflammatory bowel disease (40)
Inflation Reduction Act (6)
Influenza (30)
Intellectual property (46)
Interviews (76)
IPO (2125)
IRA (42)
Job creations (849)
Job search strategy (388)
JPM (39)
Kidney cancer (3)
Labor market (78)
Layoffs (234)
Leadership (31)
Legal (1135)
Licensing (4)
Liver cancer (17)
Longevity (5)
Lung cancer (144)
Lymphoma (90)
Machine learning (16)
Management (24)
Manufacturing (375)
Marketing (2)
MASH (56)
Medical device (421)
Medtech (428)
Mergers & acquisitions (4073)
Metabolic disorders (574)
mRNA (55)
Multiple sclerosis (39)
NASH (9)
Neurodegenerative disease (107)
Neuropsychiatric disorders (47)
Neuroscience (731)
Neurotech (1)
NextGen: Class of 2026 (641)
Non-profit (149)
Now hiring (51)
Obesity (400)
Opinion (168)
Ovarian cancer (23)
Pain (73)
Pancreatic cancer (60)
Parkinson's disease (70)
Partnered (11)
Patents (128)
Patient recruitment (92)
Peanut (5)
People (10640)
Pharmaceutical (12)
Pharmacy benefit managers (22)
Phase 1 (3095)
Phase 2 (5047)
Phase 3 (4287)
Pipeline (1629)
Policy (195)
Postmarket research (289)
Preclinical (1057)
Press Release (4)
Prostate cancer (59)
Psychedelics (28)
Radiopharmaceuticals (88)
Rare diseases (276)
Real estate (981)
Recruiting (22)
Regulatory (4083)
Reports (16)
Research institute (223)
Resumes & cover letters (99)
Rett syndrome (1)
RNA editing (9)
RSV (29)
Schizophrenia (71)
Series A (65)
Series B (43)
Service/supplier (2)
Sickle cell disease (18)
Special edition (21)
Spinal muscular atrophy (44)
Sponsored (8)
Startups (749)
Stomach cancer (10)
Supply chain (53)
Tariffs (93)
The Weekly (70)
Vaccines (210)
Venture capital (85)
Weight loss (332)
Women's health (32)
Worklife (8)
Date
Today (26)
Last 7 days (107)
Last 30 days (390)
Last 365 days (4734)
2026 (2983)
2025 (4741)
2024 (5252)
2023 (5759)
2022 (8121)
2021 (7644)
2020 (6677)
2019 (5441)
2018 (4344)
2017 (6193)
2016 (5388)
2015 (5398)
2014 (3325)
2013 (2861)
2012 (2889)
2011 (2852)
2010 (2397)
Location
Africa (186)
Alabama (6)
Arizona (17)
Arkansas (1)
Asia (9542)
Australia (942)
California (1357)
Canada (603)
China (351)
Colorado (89)
Connecticut (110)
Delaware (50)
Europe (20907)
Florida (376)
Georgia (13)
Hawaii (1)
Idaho (3)
Illinois (121)
India (55)
Indiana (60)
Iowa (2)
Japan (219)
Kansas (46)
Kentucky (2)
Louisiana (3)
Maryland (226)
Massachusetts (1139)
Michigan (27)
Minnesota (22)
Mississippi (2)
Missouri (4)
Montana (1)
Nebraska (3)
Nevada (9)
New Hampshire (3)
New Jersey (784)
New Mexico (16)
New York (388)
North Carolina (198)
Northern California (551)
Ohio (72)
Oklahoma (1)
Oregon (7)
Pennsylvania (411)
Puerto Rico (17)
Rhode Island (8)
South America (237)
South Carolina (3)
Southern California (667)
Tennessee (17)
Texas (132)
United States (5654)
Utah (22)
Virginia (23)
Washington D.C. (19)
Washington State (189)
West Virginia (1)
Wisconsin (15)
Wyoming (1)
92,203 Results for "recce pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.
July 28, 2026
·
7 min read
·
Annalee Armstrong
Business
Deep dive: Pharma CEO compensation report
Who is the highest paid CEO in all of pharma? In this special edition,
BioSpace
examines top paid CEOs and their pay packages.
June 30, 2026
·
1 min read
·
Annalee Armstrong
Career Advice
From Big Pharma to specialty: why moving closer to the patient changes everything
Working at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened thinking and leadership.
July 22, 2026
·
6 min read
·
Thomas Kolaras
Business
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA Pharma has put out its analysis. Skyrocketing sales and multiple FDA approvals helped the company shoot to the top.
May 26, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.
June 10, 2026
·
1 min read
·
Annalee Armstrong
China
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines
Recent deals from Pfizer and Bristol Myers Squibb hint at Big Pharma’s more collaborative approach to partnering with Chinese companies.
June 2, 2026
·
2 min read
·
Tristan Manalac
C-suite
Lilly, J&J CEOs top pharma’s highest paid list—again
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.
May 13, 2026
·
5 min read
·
Annalee Armstrong
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
·
3 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
1 of 9,221
Next
